Hasbro, IDEXX and TG Therapeutics raise 2026 forecasts after third-quarter revenue growth
Key Facts
Hasbro, IDEXX Laboratories and TG Therapeutics raised their financial forecasts for 2026 after reporting third-quarter results, citing revenue growth and different drivers at each company. Hasbro revenue rose 15% year over year, IDEXX revenue reached about 1,214 million dollars, up 10%, and TG Therapeutics reported total revenue of 259.9 million dollars. The companies issued higher guidance for the rest of the year, with Hasbro raising its revenue growth and operating margin forecasts, IDEXX its revenue and earnings-per-share forecasts, and TG Therapeutics its estimates for global revenue and U.S. BRIUMVI revenue. This comes as no documented numerical comparison between the results and analyst estimates is available. EL7 data recorded closing prices on November 16 of 121.02 dollars for Hasbro shares, 700.65 dollars for IDEXX shares and 62.76 dollars for TG Therapeutics shares.
At Hasbro, revenue from Wizards and Digital Gaming supported results, growing 31%, compared with increases of 4% in consumer products and 9% in entertainment. Adjusted operating profit rose to 541 million dollars, up 52% from a year earlier. The company attributed the increase to sales momentum, a favorable product mix and cost productivity. It also said Magic: The Gathering exceeded 600 million dollars in quarterly revenue for the first time, with the brand's revenue growing 34% during the quarter. Hasbro raised its full-year revenue growth forecast to 7–9% in constant currency, from 5–7%. It also raised its adjusted operating margin forecast to 27–28%, from a previous range of 25–26%.
IDEXX reported quarterly revenue of 1,214 million dollars, up 10% on both a reported and organic basis, while diluted earnings per share reached 4.01 dollars. Recurring diagnostics growth for the companion animal group was 11%, the company said. Revenue from reference laboratory diagnostic and consulting services also increased 10%. IDEXX attributed this performance to higher test volumes, new customer acquisition and realized pricing. The company raised its annual revenue forecast range to 4,741–4,767 million dollars, an increase of 32 million dollars at the midpoint compared with its previous guidance. It also raised its earnings-per-share forecast range to 14.96–15.16 dollars, an increase of 0.25 dollars at the midpoint of the previous range.
TG Therapeutics reported global revenue of 259.9 million dollars in the third quarter, including 232.6 million dollars in U.S. net revenue from BRIUMVI. U.S. product revenue increased about 52% from the same period a year earlier. Based on these results, the company raised its 2026 global revenue forecast to about 1 billion dollars, from about 950 million dollars. It also raised its forecast for U.S. net revenue from BRIUMVI to 915–920 million dollars, from 890–905 million dollars. The chief executive said the company was on track to exceed 1 billion dollars in global revenue during 2026, less than four years after BRIUMVI's launch. These figures reflect the increased guidance's reliance on product growth in the U.S. market as part of the company's total global revenue.
TG Therapeutics repurchased about 100 million dollars of its shares during the third quarter, equivalent to approximately 2.0 million shares. Cumulative repurchases through the end of the quarter reached 300 million dollars, or 8.9 million shares. In earlier moves during earnings season, IDEXX shares rose 21.9% on November 2 after the company reported third-quarter results and raised its annual forecast, according to Kiplinger. Hasbro shares also climbed 11.2% on October 20 after the company said Magic: The Gathering exceeded 600 million dollars in quarterly revenue for the first time, according to the Associated Press. Those moves relate to the dates October 2 and 20, while the November 16 prices are recorded closing prices and do not by themselves establish how much the shares rose during the period covered by the Zacks headline.